Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck

Cancer Letters

Volumn 178, Issue 2, 2002, Pages 151-159

  Katori, Hideaki ^a   Baba, Yuh ^a   Imagawa, Yukari ^a   Nishimura, Goshi ^a   Kagesato, Yuumi ^a   Takagi, Emi ^a   Ishii, Akiko ^a   Yanoma, Shunsuke ^b   Maekawa, Ryuji ^c   Yoshioka, Takayuki ^c   Nagashima, Yoji ^a   Kato, Yasumasa ^a,d   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

^d KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

Anti angiogenesis; Head and neck; Matrix metalloproteinase; Matrix metalloproteinase inhibitor; MMI 166; Squamous cell carcinoma

Indexed keywords

GELATINASE A; GELATINASE B; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; MMI 166; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ENZYME INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 18244386777     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00837-0     Document Type: Article

References (35)

1. Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymotgraphy
2. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis
3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary
4. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma
5. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours
6. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study
7. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: Implications for lymph node metastasis
8. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma
9. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma
10. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
11. How does extracellular matrix control capillary morphogenesis?
12. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
13. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
14. Experimental metastasis is suppressed in MMP-9-deficient mice
15. Recent advances in inhibitors of metalloproteinases for cancer therapy
16. Clinical potential of matrix metalloprotease inhibitors
17. Ongoing trials with matrix metalloproteinase inhibitors
18. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
19. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
20. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives
21. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
22. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor
23. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer
24. Effect of combination therapy with matrix metalloproteinase inhibitor mmi-166 and mitomycin c on the growth and liver metastasis of human colon cancer
25. The sensitivity of head and neck squamous cell carcinomas to tumor necrosis factor-α
26. INK4a and cyclin D1 in head and neck carcinoma cell lines
27. Production of trypsins by human gastric cancer cells correlates with their malignant phenotype
28. Inostamycin, an inhibitor of cytidine 5′-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): Inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line
29. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines
30. A rapid in vitro assay for quantitating the invasive potential of tumor cells
31. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells
32. Matrix metalloproteinase inhibitors: Present achievements and future prospects
33. Paradoxical stimulation of matrix metalloproteinase-9 expression in HT1080 cells by a broad-spectrum hydroxamate-based matrix metalloproteinase inhibitor
34. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
35. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I